TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors?

In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors.

TAVI y anticoagulación: ¿anticoagulantes directos o inhibidores de la vitamina K?

Cardiologists, hematologists, clinicians, and surgeons are still not sure about how to decide which drug to prescribe.

Two primary endpoints were defined: all-cause mortality (efficacy), and major bleeding (safety). Propensity score matching was used to compare both populations.

While 24,581 patients were screened, the final analysis only included 8962 patients (36.4%) who received vitamin K inhibitors and 2180 patients (24.3%) who were discharged with direct anticoagulant agents.

After 3 years of follow-up and adjusting through propensity score matching, both all-cause mortality (hazard ratio [HR]: 1.37; 95% confidence interval [CI]: 1.12 to 1.67; p < 0.005) and bleeding (HR: 1.64; 95% CI: 1.17 to 2.29; p < 0.005) favored direct anticoagulant agents.


Read also: New Evidence in Israel in Favor of Applying a Third Dose against COVID-19.


These data, combined with others, are starting to simplify post-procedure schemes. If the patient does not need anticoagulation, aspirin monotherapy suffices. On the other hand, if anticoagulation is needed, a direct inhibitor without any concomitant drugs should be prescribed.

Conclusions

This large French multicenter study with extensive follow-up of clinical events showed that direct anticoagulant agents reduce mortality and major bleeding. This research supports using direct inhibitors as the preferred option.

Original Title: TAVR Patients Requiring Anticoagulation: Direct Oral Anticoagulant or Vitamin K Antagonist?

Reference: Romain Didier et al. JACC Cardiovasc Interv. 2021 Aug 9;14(15):1704-1713. doi: 10.1016/j.jcin.2021.05.025.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...